US · Healthcare · Medical Devices
EPS came in at 0.13 against a street estimate of 0.13 — a beat of 0.0%.
Analysts rate Artivion Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $42.15.
| Fund | Stake |
|---|---|
| BlackRock Inc | 13.28% |
| FMR Inc | 5.30% |
| Delaware Management Holdings Inc | 5.04% |
| Morgan Stanley - Brokerage Accounts | 4.65% |
| Juniper Investment Co, LLC | 4.14% |
| Vanguard Capital Management, LLC | 4.00% |
| State Street Corp | 3.45% |
| Perceptive Advisors LLC | 3.36% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ARTIVION, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q2 2026: $125.8 million (up 11% YoY from $113.0 million in Q2 2025) • Six-mo | 2026-08-07 |
| Results announced · Q3 2026 ARTIVION, INC. - Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $125.8 million, up 11% GAAP basis and 9% constant currency vs | 2026-08-06 |
| Reg FD disclosure · Q2 2026 ARTIVION, INC. — FORM 8-K SUMMARY Report Date: May 18, 2026 --- HEADLINE NUMBERS • Base purchase price: $175.0 million (all cash) • Net purchase pr | 2026-05-18 |
| Shareholder vote results · Q2 2026 ARTIVION, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held May 12, 2026 • All 9 nominated directors elected to serve u | 2026-05-15 |
| Quarterly report · Q1 2026 ARTIVION, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenues Q1 2026: $116.3 million (up 17.5% from $99.0 million in Q1 2025) - Product | 2026-05-08 |
| Results announced · Q2 2026 ARTIVION INC. – Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 revenue: $116.3 million (18% GAAP growth; 12% constant currency growth vs. Q1 20 | 2026-05-07 |
| Proxy statement · Q2 2026 ARTIVION, INC. – 2026 PROXY STATEMENT SUMMARY --- CEO COMPENSATION & CHANGES • CEO J. Patrick Mackin's total compensation figures are not explicitl | 2026-04-01 |
| Annual report FY2025 ARTIVION, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Artivion, Inc. (ticker: AORT on NYSE) – medical device and tissue pre | 2026-02-18 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Artivion Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.